Understanding an Increasingly Complex Treatment Landscape in Urothelial Carcinoma: Guidance for Frontline Oncology Practitioners

Review slides with commentary in slidenotes from pharmacist and nursing experts on patient counseling, monitoring, and managing adverse events associated with avelumab, enfortumab vedotin, and erdafitinib in urothelial carcinoma.
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Format: Microsoft PowerPoint (.ppt)
File Size: 785 KB
Released: January 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Related Content

Slides on checkpoint inhibitors in first-line, second-line, and maintenance settings for urothelial carcinoma, from Clinical Care Options (CCO)

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Slides on erdafitinib, enfortumab vedotin, and sacituzumab govitecan for progressive urothelial carcinoma, from Clinical Care Options (CCO)

Petros Grivas, MD, PhD Released: February 26, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset from Clinical Care Options (CCO) exploring current and emerging first-line treatment options for patients with metastatic bladder cancer.

Matthew Galsky, MD Released: February 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue